Journal
CLINICAL INFECTIOUS DISEASES
Volume 62, Issue 4, Pages 484-490Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/civ911
Keywords
tuberculosis; fluoroquinolones; shortening regimen; REMox-TB; OFLOTUB
Categories
Funding
- NIAID NIH HHS [P30 AI094189] Funding Source: Medline
Ask authors/readers for more resources
The disappointing recent failure of fluoroquinolone-containing regimens to shorten the duration of tuberculosis treatment in costly phase 3 trials has raised serious questions about the reliability of preclinical tuberculosis models, especially mice, and the current paradigm of regimen development. Therefore we re-examined data from murine models and early-stage clinical trials on which the pivotal trials were based, concluding that phase 3 trial results were in line with preceding studies. Finally, we offer suggestions for a more efficient and integrated preclinical and clinical regimen development program where quantitative pharmacokinetic and pharmacodynamic models more predictive of curative treatment durations are set forth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available